Combining methylated SDC2 test in stool DNA, fecal immunochemical test, and tumor markers improves early detection of colorectal neoplasms
ObjectiveTo explore the value of testing methylated SDC2 (SDC2) in stool DNA combined with fecal immunochemical test (FIT) and serum tumor markers (TM) for the early detection of colorectal neoplasms.MethodsA total of 533 patients, including 150 with CRC (67 with early-stage CRC), 23 with APL, 85 wi...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-08-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1166796/full |
| _version_ | 1797746198555131904 |
|---|---|
| author | Tao Zeng Tao Zeng Zhongchao Huang Zhongchao Huang Xufa Yu Xufa Yu Li Zheng Li Zheng Tao Liu Tao Liu Boyu Tian Boyu Tian Siyu Xiao Siyu Xiao Jiahui Huang Jiahui Huang |
| author_facet | Tao Zeng Tao Zeng Zhongchao Huang Zhongchao Huang Xufa Yu Xufa Yu Li Zheng Li Zheng Tao Liu Tao Liu Boyu Tian Boyu Tian Siyu Xiao Siyu Xiao Jiahui Huang Jiahui Huang |
| author_sort | Tao Zeng |
| collection | DOAJ |
| description | ObjectiveTo explore the value of testing methylated SDC2 (SDC2) in stool DNA combined with fecal immunochemical test (FIT) and serum tumor markers (TM) for the early detection of colorectal neoplasms.MethodsA total of 533 patients, including 150 with CRC (67 with early-stage CRC), 23 with APL, 85 with non-advanced adenomas and general polyps, and 275 with benign lesions and healthy controls. SDC2 was detected by methylation-specific PCR, FIT (hemoglobin, Hb and transferrin, TF) was detected by immunoassay, and the relationships between SDC2, FIT, and clinicopathological features were analyzed. Pathological biopsy or colonoscopy were used as gold standards for diagnosis, and the diagnostic efficacy of SDC2 combined with FIT and TM in CRC and APL evaluated using receiver operating characteristic (ROC) curves.ResultsSDC2 positive rates in early-stage CRC and APL were 77.6% (38/49) and 41.2% (7/17), respectively, and combination of SDC2 with FIT increased the positive rates to 98.0% (48/49) and 82.4% (14/17). The positive rates of SDC2 combined with FIT assay in the APL and CRC groups at stages 0-IV were 82.4% (14/17), 85.7% (6/7), 100% (16/16), 100% (26/26), 97.4% (38/39), and 100% (22/22), respectively. Compared to the controls, both the CRC and APL groups showed significantly higher positive detection rates of fecal SDC2 and FIT (χ2 = 114.116, P < 0.0001 and χ2 = 85.409, P < 0.0001, respectively). Our results demonstrate a significant difference in the qualitative methods of SDC2 and FIT for the detection of colorectal neoplasms (McNemar test, P < 0.0001). ROC curve analysis revealed that the sensitivities of SDC2 and FIT, alone or in combination, for the detection of early CRC and APL were 69.9%, 86.3%, and 93.9%, respectively (all P<0.0001). When combined with CEA, the sensitivity increased to 97.3% (P<0.0001).ConclusionsSDC2 facilitates colorectal neoplasms screening, and when combined with FIT, it enhances detection. Furthermore, the combination of SDC2 with FIT and CEA maximizes overall colorectal neoplasm detection. |
| first_indexed | 2024-03-12T15:33:34Z |
| format | Article |
| id | doaj.art-99169a4f366f4717b61d5f5b0b95c65d |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-03-12T15:33:34Z |
| publishDate | 2023-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-99169a4f366f4717b61d5f5b0b95c65d2023-08-09T18:48:05ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-08-011310.3389/fonc.2023.11667961166796Combining methylated SDC2 test in stool DNA, fecal immunochemical test, and tumor markers improves early detection of colorectal neoplasmsTao Zeng0Tao Zeng1Zhongchao Huang2Zhongchao Huang3Xufa Yu4Xufa Yu5Li Zheng6Li Zheng7Tao Liu8Tao Liu9Boyu Tian10Boyu Tian11Siyu Xiao12Siyu Xiao13Jiahui Huang14Jiahui Huang15Department of Clinical Laboratory, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, ChinaBiomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, ChinaDepartment of Clinical Laboratory, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, ChinaBiomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, ChinaDepartment of Clinical Laboratory, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, ChinaBiomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, ChinaDepartment of Clinical Laboratory, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, ChinaBiomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, ChinaBiomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, ChinaDepartment of Gastroenterology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, ChinaDepartment of Clinical Laboratory, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, ChinaState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, ChinaDepartment of Clinical Laboratory, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, ChinaBiomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, ChinaDepartment of Clinical Laboratory, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, ChinaBiomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, ChinaObjectiveTo explore the value of testing methylated SDC2 (SDC2) in stool DNA combined with fecal immunochemical test (FIT) and serum tumor markers (TM) for the early detection of colorectal neoplasms.MethodsA total of 533 patients, including 150 with CRC (67 with early-stage CRC), 23 with APL, 85 with non-advanced adenomas and general polyps, and 275 with benign lesions and healthy controls. SDC2 was detected by methylation-specific PCR, FIT (hemoglobin, Hb and transferrin, TF) was detected by immunoassay, and the relationships between SDC2, FIT, and clinicopathological features were analyzed. Pathological biopsy or colonoscopy were used as gold standards for diagnosis, and the diagnostic efficacy of SDC2 combined with FIT and TM in CRC and APL evaluated using receiver operating characteristic (ROC) curves.ResultsSDC2 positive rates in early-stage CRC and APL were 77.6% (38/49) and 41.2% (7/17), respectively, and combination of SDC2 with FIT increased the positive rates to 98.0% (48/49) and 82.4% (14/17). The positive rates of SDC2 combined with FIT assay in the APL and CRC groups at stages 0-IV were 82.4% (14/17), 85.7% (6/7), 100% (16/16), 100% (26/26), 97.4% (38/39), and 100% (22/22), respectively. Compared to the controls, both the CRC and APL groups showed significantly higher positive detection rates of fecal SDC2 and FIT (χ2 = 114.116, P < 0.0001 and χ2 = 85.409, P < 0.0001, respectively). Our results demonstrate a significant difference in the qualitative methods of SDC2 and FIT for the detection of colorectal neoplasms (McNemar test, P < 0.0001). ROC curve analysis revealed that the sensitivities of SDC2 and FIT, alone or in combination, for the detection of early CRC and APL were 69.9%, 86.3%, and 93.9%, respectively (all P<0.0001). When combined with CEA, the sensitivity increased to 97.3% (P<0.0001).ConclusionsSDC2 facilitates colorectal neoplasms screening, and when combined with FIT, it enhances detection. Furthermore, the combination of SDC2 with FIT and CEA maximizes overall colorectal neoplasm detection.https://www.frontiersin.org/articles/10.3389/fonc.2023.1166796/fullSDC2fecal immunochemical testcolorectal neoplasmstumor markerscombined testing |
| spellingShingle | Tao Zeng Tao Zeng Zhongchao Huang Zhongchao Huang Xufa Yu Xufa Yu Li Zheng Li Zheng Tao Liu Tao Liu Boyu Tian Boyu Tian Siyu Xiao Siyu Xiao Jiahui Huang Jiahui Huang Combining methylated SDC2 test in stool DNA, fecal immunochemical test, and tumor markers improves early detection of colorectal neoplasms Frontiers in Oncology SDC2 fecal immunochemical test colorectal neoplasms tumor markers combined testing |
| title | Combining methylated SDC2 test in stool DNA, fecal immunochemical test, and tumor markers improves early detection of colorectal neoplasms |
| title_full | Combining methylated SDC2 test in stool DNA, fecal immunochemical test, and tumor markers improves early detection of colorectal neoplasms |
| title_fullStr | Combining methylated SDC2 test in stool DNA, fecal immunochemical test, and tumor markers improves early detection of colorectal neoplasms |
| title_full_unstemmed | Combining methylated SDC2 test in stool DNA, fecal immunochemical test, and tumor markers improves early detection of colorectal neoplasms |
| title_short | Combining methylated SDC2 test in stool DNA, fecal immunochemical test, and tumor markers improves early detection of colorectal neoplasms |
| title_sort | combining methylated sdc2 test in stool dna fecal immunochemical test and tumor markers improves early detection of colorectal neoplasms |
| topic | SDC2 fecal immunochemical test colorectal neoplasms tumor markers combined testing |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2023.1166796/full |
| work_keys_str_mv | AT taozeng combiningmethylatedsdc2testinstooldnafecalimmunochemicaltestandtumormarkersimprovesearlydetectionofcolorectalneoplasms AT taozeng combiningmethylatedsdc2testinstooldnafecalimmunochemicaltestandtumormarkersimprovesearlydetectionofcolorectalneoplasms AT zhongchaohuang combiningmethylatedsdc2testinstooldnafecalimmunochemicaltestandtumormarkersimprovesearlydetectionofcolorectalneoplasms AT zhongchaohuang combiningmethylatedsdc2testinstooldnafecalimmunochemicaltestandtumormarkersimprovesearlydetectionofcolorectalneoplasms AT xufayu combiningmethylatedsdc2testinstooldnafecalimmunochemicaltestandtumormarkersimprovesearlydetectionofcolorectalneoplasms AT xufayu combiningmethylatedsdc2testinstooldnafecalimmunochemicaltestandtumormarkersimprovesearlydetectionofcolorectalneoplasms AT lizheng combiningmethylatedsdc2testinstooldnafecalimmunochemicaltestandtumormarkersimprovesearlydetectionofcolorectalneoplasms AT lizheng combiningmethylatedsdc2testinstooldnafecalimmunochemicaltestandtumormarkersimprovesearlydetectionofcolorectalneoplasms AT taoliu combiningmethylatedsdc2testinstooldnafecalimmunochemicaltestandtumormarkersimprovesearlydetectionofcolorectalneoplasms AT taoliu combiningmethylatedsdc2testinstooldnafecalimmunochemicaltestandtumormarkersimprovesearlydetectionofcolorectalneoplasms AT boyutian combiningmethylatedsdc2testinstooldnafecalimmunochemicaltestandtumormarkersimprovesearlydetectionofcolorectalneoplasms AT boyutian combiningmethylatedsdc2testinstooldnafecalimmunochemicaltestandtumormarkersimprovesearlydetectionofcolorectalneoplasms AT siyuxiao combiningmethylatedsdc2testinstooldnafecalimmunochemicaltestandtumormarkersimprovesearlydetectionofcolorectalneoplasms AT siyuxiao combiningmethylatedsdc2testinstooldnafecalimmunochemicaltestandtumormarkersimprovesearlydetectionofcolorectalneoplasms AT jiahuihuang combiningmethylatedsdc2testinstooldnafecalimmunochemicaltestandtumormarkersimprovesearlydetectionofcolorectalneoplasms AT jiahuihuang combiningmethylatedsdc2testinstooldnafecalimmunochemicaltestandtumormarkersimprovesearlydetectionofcolorectalneoplasms |